Evidence map›Paper›PMID 34631791›Full record

ArticleFrontiers in molecular biosciences2021

Corrigendum: Silencing of lncRNA MIR497HG via CRISPR/Cas13d Induces Bladder Cancer Progression Through Promoting the Crosstalk Between Hippo/Yap and TGF-β/Smad Signaling.

Changshui Zhuang, Ying Liu, Shengqiang Fu, Chaobo Yuan, Jingwen Luo, Xueting Huang, Weifeng Yang, Wuwei Xie, Chengle Zhuang

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Changshui ZhuangDepartment of Urology, Union Shenzhen Hospital, Huazhong University of Science and Technology, Shenzhen, China.
Ying LiuShenzhen People's Hospital, The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University, Shenzhen, China.
Shengqiang FuDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Chaobo YuanEmergency Department, Union Shenzhen Hospital, Huazhong University of Science and Technology, Shenzhen, China.
Jingwen LuoShenzhen Yantian District People's Hospital, Shenzhen, China.
Xueting HuangDepartment of Thoracic Surgery, Union Shenzhen Hospital, Huazhong University of Science and Technology, Shenzhen, China.
Weifeng YangDepartment of Urology, Union Shenzhen Hospital, Huazhong University of Science and Technology, Shenzhen, China.
Wuwei XieDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.
Chengle ZhuangDepartment of Urology, Peking University Shenzhen Hospital, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fmolb.2020.616768.].

Indexed as

bladder cancerCRISPR/Cas13daysMIR497HGTGF-bYAP

Identifiers

PMID34631791
PMCPMC8496051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.